Published in Am J Trop Med Hyg on March 01, 2002
Arginase I induction during Leishmania major infection mediates the development of disease. Infect Immun (2005) 1.15
Endogenous interleukin-12 is critical for controlling the late but not the early stage of Leishmania mexicana infection in C57BL/6 mice. Infect Immun (2002) 0.86
PPAR activation induces M1 macrophage polarization via cPLA₂-COX-2 inhibition, activating ROS production against Leishmania mexicana. Biomed Res Int (2013) 0.83
Ex vivo and in vivo biological behavior of Leishmania (Viannia) shawi. Parasitol Res (2009) 0.81
Effect of ambient temperature on the clinical manifestations of experimental diffuse cutaneous leishmaniasis in a rodent model. Vector Borne Zoonotic Dis (2012) 0.78
A canine model of experimental infection with Leishmania (L.) mexicana. Parasit Vectors (2014) 0.76
Use of Optical Imaging Technology in the Validation of a New, Rapid, Cost-Effective Drug Screen as Part of a Tiered In Vivo Screening Paradigm for Development of Drugs To Treat Cutaneous Leishmaniasis. Antimicrob Agents Chemother (2017) 0.75
An RNA gene expressed during cortical development evolved rapidly in humans. Nature (2006) 7.23
Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome. Lancet (2003) 6.52
Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol (2009) 4.63
Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol (2005) 3.46
Galectin-1: a small protein with major functions. Glycobiology (2006) 3.06
Selective retention of herpes simplex virus-specific T cells in latently infected human trigeminal ganglia. Proc Natl Acad Sci U S A (2007) 2.13
The Guillain-Barré syndrome: a true case of molecular mimicry. Trends Immunol (2004) 1.96
Genetically resistant mice lacking MyD88-adapter protein display a high susceptibility to Leishmania major infection associated with a polarized Th2 response. J Immunol (2003) 1.91
Proautophagic drugs: a novel means to combat apoptosis-resistant cancers, with a special emphasis on glioblastomas. Oncologist (2007) 1.85
Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis Colon Rectum (2004) 1.79
Comparison of polymerase chain reaction methods for reliable and easy detection of congenital Trypanosoma cruzi infection. Am J Trop Med Hyg (2003) 1.75
Mother-to-child transmission of Chagas' disease in North America: why don't we do more? Matern Child Health J (2007) 1.71
Cardiotonic steroids on the road to anti-cancer therapy. Biochim Biophys Acta (2007) 1.70
Maternal Trypanosoma cruzi infection, pregnancy outcome, morbidity, and mortality of congenitally infected and non-infected newborns in Bolivia. Am J Trop Med Hyg (2004) 1.69
3-Aryl-2-quinolone derivatives: synthesis and characterization of in vitro and in vivo antitumor effects with emphasis on a new therapeutical target connected with cell migration. J Med Chem (2002) 1.59
Polarized type 1 cytokine response and cell-mediated immunity determine genetic resistance to mousepox. Proc Natl Acad Sci U S A (2004) 1.56
Transfer of central nervous system autoantigens and presentation in secondary lymphoid organs. J Immunol (2002) 1.54
iNOS-producing inflammatory dendritic cells constitute the major infected cell type during the chronic Leishmania major infection phase of C57BL/6 resistant mice. PLoS Pathog (2009) 1.53
Myelin-laden macrophages are anti-inflammatory, consistent with foam cells in multiple sclerosis. Brain (2005) 1.51
Can anti-migratory drugs be screened in vitro? A review of 2D and 3D assays for the quantitative analysis of cell migration. Med Res Rev (2007) 1.50
Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res (2010) 1.50
Cell culture processes for monoclonal antibody production. MAbs (2010) 1.48
Marked elevation of the chemokine CCL18/PARC in Gaucher disease: a novel surrogate marker for assessing therapeutic intervention. Blood (2003) 1.44
Trivanillic polyphenols with anticancer cytostatic effects through the targeting of multiple kinases and intracellular Ca2+ release. J Cell Mol Med (2012) 1.40
MyD88-dependent activation of B220-CD11b+LY-6C+ dendritic cells during Brucella melitensis infection. J Immunol (2007) 1.39
Galectins and cancer. Biochim Biophys Acta (2002) 1.37
Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia (2008) 1.34
Tenascin-C is a novel RBPJkappa-induced target gene for Notch signaling in gliomas. Cancer Res (2009) 1.34
Langerhans cell histiocytosis: fascinating dynamics of the dendritic cell-macrophage lineage. Immunol Rev (2010) 1.28
Characterization of the activities of actin-affecting drugs on tumor cell migration. Toxicol Appl Pharmacol (2005) 1.28
Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am J Clin Pathol (2004) 1.28
Congenital transmission of Trypanosoma cruzi is associated with maternal enhanced parasitemia and decreased production of interferon- gamma in response to parasite antigens. J Infect Dis (2004) 1.27
Naphthalimides and azonafides as promising anti-cancer agents. Curr Med Chem (2009) 1.25
Effective treatment of psoriasis with narrow-band UVB phototherapy is linked to suppression of the IFN and Th17 pathways. J Invest Dermatol (2011) 1.24
Chagas disease, France. Emerg Infect Dis (2008) 1.23
The Amaryllidaceae isocarbostyril narciclasine induces apoptosis by activation of the death receptor and/or mitochondrial pathways in cancer cells but not in normal fibroblasts. Neoplasia (2007) 1.22
Targeting the alpha 1 subunit of the sodium pump to combat glioblastoma cells. Neurosurgery (2008) 1.21
CD11c-expressing cells reside in the juxtavascular parenchyma and extend processes into the glia limitans of the mouse nervous system. Acta Neuropathol (2010) 1.21
The sodium pump alpha1 sub-unit: a disease progression-related target for metastatic melanoma treatment. J Cell Mol Med (2009) 1.21
Birth and rapid subcellular adaptation of a hominoid-specific CDC14 protein. PLoS Biol (2008) 1.21
Human fetuses are able to mount an adultlike CD8 T-cell response. Blood (2002) 1.18
Prevention of experimental autoimmune encephalomyelitis in common marmosets using an anti-IL-12p40 monoclonal antibody. J Immunol (2002) 1.18
Present and potential future issues in glioblastoma treatment. Expert Rev Anticancer Ther (2006) 1.17
Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression. Neoplasia (2010) 1.15
Upregulation of galectins-1 and -3 in human colon cancer and their role in regulating cell migration. Int J Cancer (2003) 1.15
Cardenolide-induced lysosomal membrane permeabilization demonstrates therapeutic benefits in experimental human non-small cell lung cancers. Neoplasia (2006) 1.14
Galectin-1 modulates human glioblastoma cell migration into the brain through modifications to the actin cytoskeleton and levels of expression of small GTPases. J Neuropathol Exp Neurol (2002) 1.14
Myd88-dependent in vivo maturation of splenic dendritic cells induced by Leishmania donovani and other Leishmania species. Infect Immun (2004) 1.14
Brain antigens in functionally distinct antigen-presenting cell populations in cervical lymph nodes in MS and EAE. J Mol Med (Berl) (2008) 1.14
The sodium pump alpha1 subunit as a potential target to combat apoptosis-resistant glioblastomas. Neoplasia (2008) 1.13
Induction of progressive demyelinating autoimmune encephalomyelitis in common marmoset monkeys using MOG34-56 peptide in incomplete freund adjuvant. J Neuropathol Exp Neurol (2010) 1.13
Digital holographic microscopy for the three-dimensional dynamic analysis of in vitro cancer cell migration. J Biomed Opt (2006) 1.12
The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. Oral Oncol (2007) 1.11
Targeting of eEF1A with Amaryllidaceae isocarbostyrils as a strategy to combat melanomas. FASEB J (2010) 1.10
Comparison of Trypanosoma cruzi lineages and levels of parasitic DNA in infected mothers and their newborns. Am J Trop Med Hyg (2007) 1.10
Identification of serum N-acetylmuramoyl-l-alanine amidase as liver peptidoglycan recognition protein 2. Biochim Biophys Acta (2005) 1.09
Proinflammatory bacterial peptidoglycan as a cofactor for the development of central nervous system autoimmune disease. J Immunol (2005) 1.08
In psoriasis lesional skin the type I interferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered. J Invest Dermatol (2004) 1.08
Autophagy, the Trojan horse to combat glioblastomas. Neurosurg Focus (2006) 1.08
Structure-activity relationship analysis of novel derivatives of narciclasine (an Amaryllidaceae isocarbostyril derivative) as potential anticancer agents. J Med Chem (2009) 1.08
Galectin 1 proangiogenic and promigratory effects in the Hs683 oligodendroglioma model are partly mediated through the control of BEX2 expression. Neoplasia (2009) 1.07
Parasitic loads in tissues of mice infected with Trypanosoma cruzi and treated with AmBisome. PLoS Negl Trop Dis (2011) 1.07
Na+/K+-ATPase alpha subunits as new targets in anticancer therapy. Expert Opin Ther Targets (2008) 1.07
Gene expression profile for ectopic versus eutopic endometrium provides new insights into endometriosis oncogenic potential. Mol Endocrinol (2008) 1.06
Evidence of galectin-1 involvement in glioma chemoresistance. Toxicol Appl Pharmacol (2008) 1.06
Growth phase of orally administered Lactobacillus strains differentially affects IgG1/IgG2a ratio for soluble antigens: implications for vaccine development. Vaccine (2003) 1.05
The cardenolide UNBS1450 is able to deactivate nuclear factor kappaB-mediated cytoprotective effects in human non-small cell lung cancer cells. Mol Cancer Ther (2006) 1.05
Knocking down galectin 1 in human hs683 glioblastoma cells impairs both angiogenesis and endoplasmic reticulum stress responses. J Neuropathol Exp Neurol (2008) 1.05
Prognostic values of galectin-3 and the macrophage migration inhibitory factor (MIF) in human colorectal cancers. Mod Pathol (2003) 1.05
Videomicroscopic extraction of specific information on cell proliferation and migration in vitro. Exp Cell Res (2008) 1.05
Experimental autoimmune encephalomyelitis in the common marmoset, a bridge between rodent EAE and multiple sclerosis for immunotherapy development. J Neuroimmune Pharmacol (2009) 1.04
Pain, mast cells, and nerves in peritoneal, ovarian, and deep infiltrating endometriosis. Fertil Steril (2006) 1.04
Increased plasma macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels in type 1 Gaucher disease. Biochim Biophys Acta (2007) 1.04
Mechanism of tumor cell-induced T-cell apoptosis mediated by galectin-1. Immunol Lett (2009) 1.04
Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia. Cancer Immunol Immunother (2004) 1.04
Modelling of multiple sclerosis: lessons learned in a non-human primate. Lancet Neurol (2004) 1.04
Galectin-1 knockdown increases sensitivity to temozolomide in a B16F10 mouse metastatic melanoma model. J Invest Dermatol (2007) 1.04
Refined prognostic evaluation in colon carcinoma using immunohistochemical galectin fingerprinting. Cancer (2003) 1.04
In situ microscopy analysis reveals local innate immune response developed around Brucella infected cells in resistant and susceptible mice. PLoS Pathog (2012) 1.04
Hidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatments. Exp Dermatol (2012) 1.04
Crucial role of gamma interferon-producing CD4+ Th1 cells but dispensable function of CD8+ T cell, B cell, Th2, and Th17 responses in the control of Brucella melitensis infection in mice. Infect Immun (2012) 1.02
Amaryllidaceae alkaloids belonging to different structural subgroups display activity against apoptosis-resistant cancer cells. J Nat Prod (2010) 1.02
In vivo detection of myelin proteins in cervical lymph nodes of MS patients using ultrasound-guided fine-needle aspiration cytology. J Neuroimmunol (2005) 1.02
High levels of myeloid-related protein 14 in human atherosclerotic plaques correlate with the characteristics of rupture-prone lesions. Arterioscler Thromb Vasc Biol (2009) 1.02
Galectins and gliomas. Brain Pathol (2009) 1.01
Evaluation of the antiproliferative activity of diterpene isonitriles from the sponge Pseudoaxinella flava in apoptosis-sensitive and apoptosis-resistant cancer cell lines. J Nat Prod (2011) 1.01
Metabolic flux analysis and pharmaceutical production. Metab Eng (2009) 1.01
[Endemic level of congenital Trypanosoma cruzi infection in the areas of maternal residence and the development of congenital Chagas disease in Bolivia]. Rev Soc Bras Med Trop (2005) 1.01
The in and out of monocytes in atherosclerotic plaques: Balancing inflammation through migration. Proc Natl Acad Sci U S A (2004) 1.00
Estrogen receptor, progesterone receptor, and glucocorticoid receptor expression in normal breast tissue, breast in situ carcinoma, and invasive breast cancer. Appl Immunohistochem Mol Morphol (2010) 1.00
Phagocytes containing a disease-promoting Toll-like receptor/Nod ligand are present in the brain during demyelinating disease in primates. Am J Pathol (2006) 1.00
Galectin-1 knocking down in human U87 glioblastoma cells alters their gene expression pattern. Biochem Biophys Res Commun (2005) 1.00